• OncologyTube Cancer Articles, News and Videos

      Site: OncologyTube Cancer Articles, News and Videos

    • Search in
    • Categories
    • Tags
    • Date within
    • Views
    • 0
      • Portuguese
      • Spanish
      • Italian
      • Greek (Greece)
      • Sinhala
      • Polish
      • Arabic (Saudi Arabia)
      • Swedish (Sweden)
      • Portuguese (Brazil)
      • Hindi (India)
      • English (Australia)
      • Hebrew (Israel)
      • Czech
      • Hungarian (Hungary)
      • Chinese
      • Turkish
      • Japanese (Japan)
      • Dutch
      • French
      • German
      • Chinese (Traditional Han, Taiwan)
      • Korean (South Korea)
      • Thai
      • Spanish (Chile)
      • English (United States)
      • Russian
      • Danish (Denmark)
  • Home
  • Trending

  • Login

  • Quick Links
  • Self Serve Advertising Portal - Buy Ads Now! No Contracts!
  • How To Self Record An Interview and Presentations
  • Schedule A Remote Interview!
  • Check Out Our Blog
  • Advertising Specifications
  • Publisher Calendar

  • Mobile
  • Connect Mobile App

  • Audio and Video
  • Videos
  • Audio

  • Channels
  • Browse Channels

  • Categories
  • Acute Lymphoblastic Leukemia 5616
  • Acute Myelogenous Leukemia 277
  • Bladder 111
  • Bone Metastases 7
  • Brain 90
  • Breast 585
  • Business Management 5
  • Cervical 18
  • Chronic Lymphocytic Leukemia 216
  • Chronic Myelogenous Leukemia 54
  • Colorectal 184
  • Conference Coverage 1
  • COVID-19 43
  • Gastrointestinal 182
  • General 350
  • Genitourinary 6
  • Head and Neck 125
  • Help 3
  • Hematologic Malignancies 213
  • Hodgkin Lymphoma 35
  • Imaging 2
  • Immunotherapy 182
  • Kidney 399
  • Liver 41
  • Lung 108
  • Lymphoma 247
  • Melanoma and Skin 111
  • Multiple Myeloma 545
  • Myeloproliferative Disease 41
  • News 152
  • Non-Hodgkin Lymphoma 82
  • Non-Small Cell Lung Cancer 638
  • Other 525
  • Ovarian 67
  • Pancreatic 112
  • Patient Resources 51
  • Pediatric 7
  • Prostate 306
  • Sarcoma 15
  • Sickle Cell 22
  • Small Cell Lung Cancer 83
  • Supportive Care 51
  • Testicular 3
  • Urology 16
  • Uterine 10

  • Install
  • Play a Link
  • About
  • Contact
Jeremy Sharib, MD @DukeSurgery #ASCOGI22 #GI22 #HAI #GICancer #Research HAI Therapy Program
0:06:42

Jeremy Sharib, MD @DukeSurgery #ASCOGI22 #GI22 #HAI #GICancer #Research HAI Therapy Program

Jeremy Sharib, MD, Complex General Surgical Oncology Fellow at Duke University. In this interview, he speaks about ASCO GI 2022 Abstract - Perioperative and oncologic outcomes of hepatic artery infusion pump therapy at an expanding HAI program.


Origins:

Unresectable or resected colorectal liver metastases (CRLM) and unresectable intrahepatic cholangiocarcinoma are treated with hepatic artery infusion (HAI) (ICC). Historically, HAI was only performed at a few specialist sites; now, the number of new centers is growing. We recently discussed the safety results of our first year of HAI therapy. We now have results for an enlarged cohort of 62 patients in an established HAI program, including safety, feasibility, efficacy, and oncologic outcomes.

Methodologies:

Patients were assessed for demographics and perioperative outcomes after being selected for HAI through a multidisciplinary assessment. RECIST 1.1 was used to calculate the objective liver response. The Kaplan-Meier method was used to determine hepatic and extrahepatic progression-free survival (PFS) on an intent-to-treat basis.

Findings:

From November 2018 to September 2021, 62 patients were treated with HAI: 46 for unresectable CRLM, 8 as adjuvant HAI for resected CRLM, and 8 for unresectable ICC. The median age was 54.5 years (range 32-80), 58 percent of the participants were men, and 97 percent had previously had chemotherapy (median 12 cycles, range 0-66). Hepatectomy (18, 29 percent) and/or colectomy/proctectomy (27, 43.5 percent) were done at the same time as pump insertion, with 19 (30.6 percent) done robotically. The average operating duration was 265 minutes (range 130-526), with an estimated blood loss of 100 mL (range 22-1000) and a 5-day stay (range 1-19). In 14% of cases, HAI-related problems occurred (Table). Floxuridine (FUDR) was started in 95 percent of patients 18.5 days following surgery on average. Hepatic disease control was obtained in 86 percent (8 partial responses [PR], 22 stable disease [SD], 5 progressed [PD]), and 89 percent (1 complete response, 8 PR, 8 SD, 2 PD) of the 38 patients who underwent HAI for unresectable CRLM and had measurable disease on imaging. The median PFS, hepatic PFS, and extrahepatic PFS were 13 months, 13 months, and 13 months, respectively, for patients with at least 3 months of follow-up.

Outcomes:

HAI can be given to well-selected patients with CRLM and ICC in a safe and effective manner. New programs with adequate expertise can achieve response rates, disease control, and PFS in highly treated patients with unresectable CRLM that are equivalent to high-volume facilities. These findings back up the newly founded HAI Consortium's objective of critically evaluating efficacy and innovation in HAI therapy through multi-institutional collaboration and modern prospective studies.

116 Views
1 year Ago
Gastrointestinal GI Cancer Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Gastrointestinal

Esophageal Adenocarcinoma: New Treatments & Hope in Oncology
Esophageal Adenocarcinoma: New Treatments & Hope in Oncology
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
30 Views
Dana Farber Cancer Institute
1 month Ago
Combination Immunotherapy for Advanced Upper GI Cancers: STAR-221
0:09:34
Combination Immunotherapy for Advanced Upper GI Cancers: STAR-221
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
87 Views
Dana Farber Cancer Institute
2 months Ago
Induction Chemotherapy with FTD/TPI and Oxaliplatin in Resectable EGAC: Preliminary Phase II Study Results
0:17:05
Induction Chemotherapy with FTD/TPI and Oxaliplatin in Resectable EGAC: Preliminary Phase II Study Results
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
63 Views
Oncology Conferences
2 months Ago
Trimodality: In addition to Trastuzumab for HER2+ Esophageal Adenocarcinoma: NRG Oncology RTOG 1010 Phase III Trial Lisa Kachnic MD
0:13:28
Trimodality: In addition to Trastuzumab for HER2+ Esophageal Adenocarcinoma: NRG Oncology RTOG 1010 Phase III Trial L...
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
109 Views
Lisa Kachnic, MD, FASTRO
5 months Ago
Gastrointestinal Malignancies Research Advancements: [Slides] Insights from Farshid Dayyani, MD
0:21:22
Gastrointestinal Malignancies Research Advancements: [Slides] Insights from Farshid Dayyani, MD
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
139 Views
Farshid Dayyani, MD
6 months Ago
ASCO 2022 Esophageal Cancer Question & Answer
0:07:23
ASCO 2022 Esophageal Cancer Question & Answer
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
10 Views
MOASC
1 year Ago
ASCO 2022 Esophageal In-Depth Slides: MOASC Spotlight
0:29:20
ASCO 2022 Esophageal In-Depth Slides: MOASC Spotlight
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
239 Views
MOASC
1 year Ago
Article: Transcript: What Is ECOG-ACRIN EA2142? And Why Should You Care? - Jennifer R. Eads, MD @PennMedicine #ASCO22 #OncoTwitter
Article: Transcript: What Is ECOG-ACRIN EA2142? And Why Should You Care? - Jennifer R. Eads, MD @PennMedicine #ASCO22...
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
17 Views
Annual Meeting
1 year Ago
Transcript Anal Cancer in HIV patients, ANCHOR Study Results
Transcript Anal Cancer in HIV patients, ANCHOR Study Results
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
17 Views
Cancer News
1 year Ago
Article: Transcript: How Immune Checkpoint Inhibitors Get Scored With 27-gene IO - Matthew Varga, PhD @OncocyteCorp #ASCO22 #OncoTwitter
Article: Transcript: How Immune Checkpoint Inhibitors Get Scored With 27-gene IO - Matthew Varga, PhD @OncocyteCorp #...
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
13 Views
Annual Meeting
1 year Ago
Audio: What Is ECOG-ACRIN EA2142? And Why Should You Care? - Jennifer R. Eads, MD @PennMedicine #ASCO22 #OncoTwitter
0:07:33
Audio: What Is ECOG-ACRIN EA2142? And Why Should You Care? - Jennifer R. Eads, MD @PennMedicine #ASCO22 #OncoTwitter
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
7 Views
Annual Meeting
1 year Ago
Platinum Chemotherapy vs TemozolomideCapecitabine for Advanced GEPNENs: ECOG-ACRIN EA2142 Results Jennifer Eads MD
0:07:33
Platinum Chemotherapy vs TemozolomideCapecitabine for Advanced GEPNENs: ECOG-ACRIN EA2142 Results Jennifer Eads MD
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
337 Views
Jennifer Eads, MD
1 year Ago

comments@oncologytube.com Copyright 2023 Medicus Networks, Inc. 45121 Morgan Heights Rd. Temecula, CA 92592 - 1 (951) 944-2173